IP Library › Granted Patent US 12,577,307
Granted Patent B2
US 12,577,307 · App. 17/290,197 · Granted Mar 17, 2026

Method and medicament for treating cancer unresponsive to PD-1/PD-L1 signaling inhibitor

Inventors: Nobuyuki Ishikura (Kanagawa, JP); Toshiki Iwai (Kanagawa, JP); Masamichi Sugimoto (Kanagawa, JP)
Assignee: Genentech, Inc.
C07K16/2827A61P35/00C07K16/22C07K16/2818A61K39/00A61K2039/507
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,577,307
App. No.
17/290,197
Granted
Mar 17, 2026
Kind
B2
Abstract

The present invention relates to medicaments, treatment methods, kits, and uses for treating cancer in individuals, characterized in that a VEGF signaling inhibitor and a PD-1/PD-L1 signaling inhibitor are administered in combination, as well as VEGF signaling inhibitors, PD-1/PD-L1 signaling inhibitors, and combinations thereof.

Claims (11)

1 . A method of treating cancer resistant to a PD-1/PD-L1 signaling inhibitor in an individual, wherein the method comprises

examining the individual for the presence or absence of resistance to a PD-1/PD-L1 signaling inhibitor,

selecting the individual for treatment based upon the determination that the individual has cancer resistant to a PD-1/PD-L1 signaling inhibitor, and

administering bevacizumab and MPDL3280A to the individual.

2 . The method of claim 1 , wherein the MPDL3280A and the bevacizumab are administered in combination.

3 . The method of claim 1 , wherein the MPDL3280A and the bevacizumab are administered concurrently, separately, or sequentially.

4 . The method of claim 3 , wherein the MPDL3280A and the bevacizumab are administered sequentially.

5 . The method of claim 3 , wherein the MPDL3280A and the bevacizumab are administered separately.

6 . The method of claim 1 , wherein the cancer is ovarian cancer or colon cancer.

7 . The method of claim 1 , wherein the PD-1/PD-L1 signaling inhibitor is MPDL3280A.

8 . The method of claim 1 , wherein the cancer is ovarian cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2025
From: ISHIKURA, NOBUYUKI; IWAI, TOSHIKI; SUGIMOTO, MASAMICHI
To: CHUGAI SEIYAKU KABUSHIKI KAISHA
Reel/Frame 072705/0898 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2025
From: CHUGAI SEIYAKU KABUSHIKI KAISHA
To: GENENTECH, INC.
Reel/Frame 072706/0204 →
Priority Claims (1)
JP 2018-206076 · Oct 31, 2018 · national
Continuity (1)
Related Publication 20210388090A1 · Dec 16, 2021
References Cited (43)
US 8217149B2 · Irving · 2012 [cited by applicant]
US 9920123B2 · Irving · 2018 [cited by applicant]
US 20100203056A1 · Irving · 2010 [cited by applicant]
US 20130045200A1 · Irving · 2013 [cited by applicant]
US 20130045201A1 · Irving · 2013 [cited by applicant]
US 20130045202A1 · Irving · 2013 [cited by applicant]
US 20140065135A1 · Irving · 2014 [cited by applicant]
US 20150322153A1 · Irving · 2015 [cited by applicant]
US 20160222117A1 · Irving · 2016 [cited by applicant]
US 20170107287A1 · Irving · 2017 [cited by applicant]
US 20190016807A1 · Irving · 2019 [cited by applicant]
US 20210032345A1 · Irving et al. · 2021 [cited by applicant]
JP 2012511329A · 2012 [cited by applicant]
JP 2017506227A · 2017 [cited by applicant]
JP 2018522850A · 2018 [cited by applicant]
JP 2018522887A · 2018 [cited by applicant]
JP 2018529375A · 2018 [cited by applicant]
WO 2010077634A1 · 2010 [cited by applicant]
WO 2015095418A1 · 2015 [cited by applicant]
WO 2015119930A1 · 2015 [cited by applicant]
WO 2016205277A1 · 2016 [cited by applicant]
WO 2017011666A1 · 2017 [cited by applicant]
WO 2017020802A1 · 2017 [cited by applicant]
WO 2018160841A1 · 2018 [cited by applicant]
Sznol et al., Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology, vol. 33, No. 7, suppl. 410, M… [cited by examiner]
Bendell et al., Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or Folfox in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, vol. 33, No. 3, … [cited by examiner]
2015. [cited by examiner]
Chen, D.S. et al. (Jul./Aug. 2018). “Combinations of Bevacizumab With Cancer Immunotherapy,” Cancer J. 24(4):193-204. [cited by applicant]
International Preliminary Report on Patentability, issued Apr. 27, 2021, for PCT Application No. PCT/IB2019/058848, filed Oct. 17, 2019, 6 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Nov. 26, 2019, for PCT Application No. PCT/IB2019/058848, filed Oct. 17, 2019, 10 pages. [cited by applicant]
Meder, L. et al. (May 18, 2018). “Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer,” Cancer Research 78(15):4270-4281. [cited by applicant]
U.S. Appl. No. 17/108,983, Irving et al., filed Dec. 1, 2020.(Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004). [cited by applicant]
U.S. Appl. No. 17/398,842, Irving et al., filed Aug. 10, 2021.(Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004). [cited by applicant]
Weber, W.A. (2009). “Assessing Tumor Response to Therapy,” J. Nucl. Med. 50:1S-10S. [cited by applicant]
WHO Drug Information (2014). “International Nonproprietary Names From Pharmaceutical Substances (INN),” INN 28(4):485-563. [cited by applicant]
Constantinidou, A. et al. (Feb. 2019, e-pub. Sep. 28, 2018). “Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A New Era In Cancer Active Immunotherapy,” Pharmacology & Therapeutics, 194:84-106. [cited by applicant]
Extended European Search Report, dated Aug. 5, 2022, for European Patent Application No. 19880708.03, 13 pages. [cited by applicant]
Gao, X, et al. (Jul./Aug. 1, 2018). “Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma,” Cancer Journal 24(4):171-179. [cited by applicant]
McDermott, D. et al. (Jun. 4, 2018). “Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination With Bevacizumab Versus Sunitinib in Renal Cell Carcinoma,” Nature Medicine 24(6):749-… [cited by applicant]
O'Donnell, U.S et al. (Jan. 2017, e-pub. Nov. 27, 2016). “Resistance to PD1/PDL1 Checkpoint Inhibition,” Cancer Treatment Reviews 52:71-81. [cited by applicant]
Socinski, M.A. et al. (Jun. 14, 2018). “Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC,” New England Journal of Medicine 378(24):2288-2301. [cited by applicant]
Zhang, L. et al. (Apr. 26, 2019). “Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition,” Frontiers in Immunology … [cited by applicant]
Gaillard, S.L. et al. (2016). “The Role of Immune Checkpoint Inhibition in the Treatment of Ovarian Cancer,” Gynecologic Oncology Research and Practice 3:11, 14 pages. [cited by applicant]